Aster Capital Management
IONS icon

Aster Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Aster Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-190
Closed -$15.1K – 1136
2026
Q2 		$15.1K Sell
190
-360
-65% -$27.1K ﹤0.01% 626
2026
Q1 		$16.6K Buy
550
+535
+3,567% +$42.2K 0.01% 572
2025
Q4 		$1.19K Buy
+15
New +$1.13K ﹤0.01% 999

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Aster Capital Management's IONS Position: Q3 2026 in Review

Aster Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2026, closing a stake of 190 shares — an estimated $15.1K sold.

Aster Capital Management first reported a position in IONS in Q4 2025 and held it in 3 quarters. The position peaked at $16.6K in Q1 2026. 351 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Aster Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Aster Capital Management sold 190 Ionis Pharmaceuticals shares in Q3 2026, an estimated $15.1K.
  • Aster Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Aster Capital Management's Ionis Pharmaceuticals position peaked at $16.6K in Q1 2026.
  • 351 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.